Abstract: The aim of this study was to quantify and characterize the scientific output from the Swedish Prescribed Drug Register (SPDR) the first decade after its establishment. A systematic literature search was performed in Medline, EMBASE and PubMed (2005-2014). Additional publications were identified by personal knowledge, reference lists, contact with active authors and a citation search in Web of Sciences. Publications using SPDR data were included in the analysis and characterized regarding study type, presence of patient-level record linkage, target population and topic. A total of 719 publications were identified in the literature search and an additional 148 by other strategies. Three hundred and thirty-eight studies fulfilled the inclusion criteria. The majority were analytic (n = 166; 49.1%) or descriptive (n = 100; 29.5%). The remaining studies focused on validation (n = 20; 5.9%), health economics (n = 16; 4.7%) or miscellaneous (n = 36; 10.7%). The analytic studies investigating effects of drug exposure focused mainly on safety (n = 46) and/or effectiveness (n = 24). The first publications appeared in 2007 (n = 6), and in 2014, 90 articles using SPDR were published. Over the years, linkage with other registers using the personal identity number increased (0-88.9% of the publications). The population was often selected by age (49.7%), condition (45.0%) and/or drug (22.8%) and concerned predominantly psychiatric (29.0%) and cardiovascular (20.4%) diseases. In conclusion, this study illustrates that the establishment of a nationwide individual-based register on dispensed prescription drugs facilitates an encouraging development of pharmacoepidemiological research, both regarding the number of publications and the scientific level of the analyses.
Increased availability of register data on drug treatment has contributed to the rapid developments within pharmacoepidemiology [1] [2] [3] . In the Nordic prescription databases, established 1993 to 2006, detailed and comprehensive nationwide information on dispensed drugs, patient and prescriber is available [4] . In Sweden, the Swedish Prescribed Drug Register (SPDR) was expanded to include the identity of the patient on 1 July 2005 [5] . Thus, since then and for research purposes after ethics application [6] , the unique personal identity number given to all Swedish citizens has allowed linkage between drug dispensing data and other registers [7] .
The Swedish Prescribed Drug Register now contains one decade of patient-level data on all dispensed prescription drugs in Sweden. The first 10 calender years of SPDR include purchases of 891 million prescriptions and 44,829 million defined daily doses [8] . Each year, drug purchases by more than 6 million inhabitants are registered in SPDR [8] , representing about two-thirds of the Swedish population.
As the establishment of an individual-based register on dispensed prescription drugs can be questioned on the basis of integrity issues, it is important to balance these risks with potential benefits, for example the contribution of the register to scientific knowledge. The scientific output from the Nordic prescription databases has been summarized [9] . However, that review was based on publications up to 2010 and included only 61 studies from SPDR. Thus, considering the developments within pharmacoepidemiology the latest years, an update is warranted.
In this study, we aimed to quantify and characterize the scientific output from SPDR from the start in 2005 up to the end of 2014, that is the first decade of patient-level data in this register.
Materials and Methods
Systematic literature searches were performed by research librarians in Medline, EMBASE and PubMed for the period of January 2005 to December 2014. The first search, including references up to 2013, was performed on 25 June 2014. An updating search on the publications of 2014 was performed on 26 May 2015. A broad search strategy was used, with combinations of alternative wordings of 'drug', 'register' and 'Swedish'. A detailed description of the search strategies is available in Appendix S1.
All authors screened the publications identified in the search, and included, during consensus discussions, studies published within the study period (not ePub ahead of print) where SPDR had been used, regardless of language. Additional studies, published in peer-reviewed journals, were identified by personal knowledge, screening of reference lists and PubMed searches on Swedish authors known by the Author for correspondence: Susanna M. Wallerstedt, Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, SE-413 90 Gothenburg, Sweden (fax +46 31 786 31 64, e-mail susanna. wallerstedt@pharm.gu.se).
authors to publish within pharmacoepidemiology. Eventually, first and last authors identified to have authored >3 papers with SPDR data were contacted with an inquiry to provide their SPDR publications, and Web of Sciences was searched to obtain articles which had cited the first paper describing SPDR [5] .
Two authors together characterized the publications regarding study type (descriptive, analytic, validation, health economics or miscellaneous; mutually exclusive). The assessments were based on the text in the abstract. When the information therein was not sufficient, we based the assessments on the full publication.
We categorized studies as descriptive if they described drug treatment patterns. These studies were further classified as either basic or advanced. The former had a focus on age, sex, regional comparisons and/or time trends, while the latter focused on aspects beyond these.
We categorized studies as analytic if the design and the reporting of results indicated that the authors had expanded the scope of the analyses outside pure description. Analytic studies were further classified according to the major role for the SPDR data, that is if the dispensed prescription drug data were used as outcome variables or to determine exposure. The former may be considered as being analytic drug utilization studies. For these, we also agreed on the topic/s/ of the study. The following topics were agreed upon beforehand: patient compliance/persistence, prescribing quality, equity including socio-economics, abuse, international comparison, evaluation of intervention and other. For analytic studies where SPDR data were used to determine exposure, we agreed as to whether they had effectiveness and/or safety in focus. If not, they were classified as other.
To be categorized as a validation study, the main focus of the study was to explicitly study data or methodology, for example to validate clinical information in registers or to validate methods for analysing register data. We categorized studies with a focus on costs, for example cost-of-illness or cost-effectiveness, as health economics studies. Studies not fitting the above mentioned types were classified as miscellaneous.
The studies were further characterized regarding the prevalence of record linkage using the unique personal identity number, and the register/s/ or data sources used. For major health registers handled by the National Board of Health and Welfare [10] , linkage was recorded separately for each register (Patient register including, e.g. hospital admission and discharge dates, diagnoses and procedures [11] , Cause of death register [12] , Medical birth register [13] , Cancer register [14] ). Data retrieved from Statistics Sweden administering civic information including, for example migration [15] and socio-economic characteristics [16] , healthcare quality registers focusing on certain conditions or procedures [17] or regional databases with detailed administrative information on healthcare consumption [18] were registered as coming from these sources. As medical records include extensive health information, linkage to this data source was recorded separately [19] .
Finally, we determined if the studies included the total population in the country or if the studied population was selected according to age, condition and/or specific drugs/groups of drugs. For all studies, we recorded the therapeutic areas focused upon in the study. We also recorded if the national indicators for prescribing quality in the elderly [20] were used. To explore the dissemination of SPDR in the research society, we summarized individuals first authoring the publications as well as the journals in which the papers were published.
Statistics. Descriptive analyses were performed with SPSS (IBM SPSS Statistics for WINDOWS, Version 22.0, Armonk, NY, USA).
Results
A total of 719 publications were identified in the literature search and an additional 148 by other strategies ( fig. 1 ). A total of 338 studies fulfilled the inclusion criteria and were included in the analysis (Appendix S2). The publications were written in English (n = 328; 97.0%) and Swedish (n = 10; 3.0%).
During the whole study period, the majority of the publications were analytic (n = 166; 49.1%) or descriptive (n = 100; 29.5%), whereas validation and health economics studies were less frequent (n = 20; 5.9% and n = 16; 4.7%, respectively) (table 1). The majority (63.0%) of the descriptive studies were advanced, that is focused on aspects beyond age, sex, regional comparisons and time trends. Although no formal classification was made concerning these studies, many concerned prescribing quality (n = 23; 36.5%). This was also the focus of 11.0% of the analytic studies using drug dispensing data for outcome variables, but equity and patient compliance/persistence were more common focuses in these studies (33.0% and 16.5%, respectively). In 26 (28.6%) analytic studies with drug use as outcome, this parameter was used as a proxy for disease. The focus of the analytic publications studying effects of drug exposure was primarily safety (61.3%) and/or effectiveness (32.0%).
The first publications appeared in 2007 (n = 6), and in 2014, 90 articles using SPDR were published ( fig. 2) . In 2007, all six studies were descriptive. Three studies were categorized as basic, that is had a focus on age, sex, regional comparisons and/or time trends, whereas the other three studies were advanced, that is focused on aspects beyond that. In 2014, 25 studies (27.8%) were descriptive (11 basic and 14 advanced), and 44 (48.9%) studies were analytic. Among the latter, SPDR data were used either for outcome variables (n = 17) or to determine exposure (n = 27).
Linkage to other registers by the personal identity number was increasingly used during the study period ( fig. 3) . In 2007, none of the studies used this kind of record linkage, and in 2014, 80 (88.9%) studies contained SPDR data linked at the patient level with data from other sources. During the whole decade, 262 (77.5%) studies used record linkage. Linkage was most often performed with other major health registers handled within the National Board of Health and Welfare (n = 190; 56.2%), that is the agency responsible for SPDR. Civic information from Statistics Sweden was also frequently used for patient-level record linkage (n = 116; 34.2%).
In 306 (90.5%) publications, the population was selected, and in 32 (9.5%) publications, no population selection was mentioned (table 1). In 218 (64.5%) publications, the population was restricted by one parameter only, that is age, condition or drugs/groups of drugs. Among populations selected by condition, the most frequent ones were cardiovascular disease including atrial fibrillation (16.4%) and pregnancy (11.8%). Among populations selected by dispensed drug/s/, the most frequent ones concerned prevention for cardiovascular disease (31.2%) and psychotropic drugs (16.9%). In 16 studies (4.7%), national indicators of prescribing quality were used.
In all, 209 different persons had authored the publications as first name, 151 (72.2%) authors first authoring one publication only. The articles were published in 164 different journals, most frequently the European Journal of Clinical Pharmacology (n = 24) and Pharmacoepidemiology and Drug Safety (n = 22). There were also articles published within high-impact journals with a more general scope, such as the British Medical Journal (n = 8), the Journal of American Medicine Association (n = 3), the New England Journal of Medicine (n = 2) and the Lancet (n = 1).
Discussion
Our systematic review illustrates the contributions to research upon the establishment of a national register with individual level data on dispensed prescription drugs. Indeed, the 338 scientific studies published during the first decade after SPDR was established illustrate the magnitude of this contribution. Record linkage was increasingly used, and the studies targeted various populations, covered most therapeutic areas and included a broad range of study types and topics. Thus, SPDR has contributed considerably to new knowledge on drug therapy in clinical practice.
Interestingly, the first studies appeared as early as 2007, that is within 2 years of the establishment of SPDR. As could be expected, these studies were descriptive. Analytic studies emerged in 2008, and in 2014, they constituted almost half of the publications. The later emergence of analytic studies may be explained by the fact that these studies require more data and longer follow-up. Further, despite the Nordic tradition within epidemiology [10] , analytic pharmacoepidemiological studies may require a learning period within the research society. Indeed, register data on dispensed prescription drugs may include challenges even for experienced epidemiologists, for example on how to determine exposure. The increase in the proportion of studies linking SPDR data to other data sources may also indicate a learning period from another perspective. Indeed, although linkage of data between registers held by different national agencies has been performed for many years, it can take time to form legally acceptable routines for data handling and linkage with other data sources, such as regional registers and healthcare quality registers.
As validation of data and methodology is the basis for research, it is reassuring to note that validation studies started to appear in 2009 and have continued to appear every year since then. They include for instance validation of data from different registers, including linkage with questionnaire data, and validation of methods to estimate outcomes. Indeed, the unique personal identity number enabling linkage between different sources of information constitutes a good basis for validation. Doubtless, there is room for more validation studies for methodological advancements [1] .
Concerning topics of analytic studies where SPDR data were used for outcome variables, it may not be surprising that equity was often in focus, concerning for example level of education, income and country of birth. Indeed, as health care in Sweden is a public responsibility, financed primarily through taxes, Swedish regulations stipulate that the healthcare system shall provide good care on equal terms to all [21] . This is a challenge, and both descriptive studies illustrating differences in drug treatment between patient groups and analytic studies focusing on underlying mechanisms may be valuable tools to achieve the goal. Noteworthy, prescribing quality was often the focus of both advanced descriptive studies and analytic drug utilization studies. Further, the national indicators of prescribing quality for the elderly were used in several publications. In this context, it may be of interest to point at recent validation studies. Indeed, although often used in pharmacoepidemiological research, polypharmacy indicators give limited information on the quality of drug treatment [22] . However, the number of drugs in the medication list may be a valuable proxy for burden of disease [23] . Further, drug-specific indicators of prescribing quality, although easy to apply on register data, have limitations when it comes to the concurrent validity, that is, how well they correlate with a gold standard for drug treatment quality [24, 25] . In fact, the specificity is generally high, but the sensitivity is low. Thus, general measures of quality of drug treatment are hard to define, and patient-level linkage between register data and medical records may contribute to deeper knowledge within this topic. However, our study shows that, so far, relatively few studies have linked data between SPDR and medical records. Although not specifically investigated and reported in this study, linkage between drug dispensing data and patient-reported use of drugs may also be a valuable strategy to learn more about the quality of drug treatment [26] .
The topic of several analytic studies with drug use as outcome was categorized as 'Other'. In these cases, the beforehand set topics were not applicable. An explanation for this is that our search strategy identified publications where data from SPDR had been used for other purposes than traditional pharmacoepidemiology. Indeed, our results indicate that knowledge on the existence of SPDR is quite well spread as most therapeutic areas were represented in this review, and the publications were first-authored by many different researchers. These findings illustrate a successful dissemination within the academic society of the availability of SPDR data for research purposes.
Pharmacoepidemiological studies are generally subject to three sources of bias; information bias, selection bias and confounding [27] . There may theoretically be a lower risk of information bias when SPDR is used as it covers all citizens from birth to death. Furthermore, the potential of patient-level linkage, retrieving other relevant data, facilitates the use of propensity scores and other matching algorithms to minimize confounding [28, 29] . However, access to high-quality data does not ensure that researchers use appropriate methods to address methodological challenges. The mix of high-and lowranked journals publishing studies using SPDR data in the present study may indicate that quality is divergent.
The most important strength of this review is that it gives a comprehensive picture of the scientific output from an individual-based register on dispensed prescription drugs during the first 10 calendar years after its establishment. Although some publications may have been missed, the fact that we have used 4 May also be referred to as analytic drug utilization studies. 5 Percentage of total in this subgroup of studies.
several strategies to identify relevant publications strengthens the review. Interestingly, the broad librarian search could only identify 190 of the 339 studies (56%) included in the review. This may be explained by the fact that no consensus has been reached within the research society on how to refer to SPDR. Further, the data source may not be explicitly expressed in the abstract, in particular if the publication is not a traditional pharmacoepidemiological study. A limitation of the study is that the classification of studies was not always crystal clear, and required, from time to time, intense discussions. Nevertheless, we reached consensus on all assessments. Summarized, this review illustrates the contributions to pharmacoepidemiological research upon the establishment of a nationwide individual-based drug register with the potential of patient-level linkage to other registers. 
